Takeda (TYO:4502) aims to include its dengue shot in India's state immunization program after local regulators approved it, Nikkei Asia reported Wednesday, citing head of intercontinental markets Mahender Nayak.
The newly approved shot, Qdenga, works against the mosquito-borne illness and covers all four viral strains, the news daily said.
Nayak said Takeda's strategic focus is on securing national program status to maximize public access, the publication said.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.